|NYSE: MRK||Healthcare / Drug Manufacturers / USA|
|110.17||+1.56||+1.44%||Vol 1.66M||1Y Perf 21.38%|
|Jun 8th, 2023 10:43 DELAYED|
|0.02 0.02%||- -|
|Target Price||115.93||Analyst Rating||Strong Buy 1.44|
|Potential %||5.22||Finscreener Ranking||★★+ 46.87|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★+ 47.83|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★ 57.37|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||★★+ 43.52|
|Price Range Ratio 52W %||74.10||Earnings Rating||Strong Buy|
|Market Cap||279.55B||Earnings Date||27th Jul 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Jul 2023|
|Estimated EPS Next Report||1.85|
|EPS Growth Next 5 Years %||8.30|
|Avg. Weekly Volume||7.03M|
|Avg. Monthly Volume||6.31M|
|Avg. Quarterly Volume||7.00M|
Merck & Company Inc. (NYSE: MRK) stock closed at 108.61 per share at the end of the most recent trading day (a -1.27% change compared to the prior day closing price) with a volume of 11.64M shares and market capitalization of 279.55B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. CEO is Robert M. Davis.
The one-year performance of Merck & Company Inc. stock is 21.38%, while year-to-date (YTD) performance is -2.11%. MRK stock has a five-year performance of 73.55%. Its 52-week range is between 83.05 and 119.65, which gives MRK stock a 52-week price range ratio of 74.10%
Merck & Company Inc. currently has a PE ratio of 19.10, a price-to-book (PB) ratio of 6.55, a price-to-sale (PS) ratio of 6.16, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of 16.38%, a ROC of 23.41% and a ROE of 40.81%. The company’s profit margin is 25.32%, its EBITDA margin is 36.70%, and its revenue ttm is $45.45 Billion , which makes it $17.93 revenue per share.
Of the last four earnings reports from Merck & Company Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.85 for the next earnings report. Merck & Company Inc.’s next earnings report date is 27th Jul 2023.
The consensus rating of Wall Street analysts for Merck & Company Inc. is Strong Buy (1.44), with a target price of $115.93, which is +5.22% compared to the current price. The earnings rating for Merck & Company Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Merck & Company Inc. has a dividend yield of 2.65% with a dividend per share of $2.92 and a payout ratio of 104.00%.
Merck & Company Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.82, ATR14 : 2.32, CCI20 : -151.44, Chaikin Money Flow : -0.09, MACD : -1.20, Money Flow Index : 41.52, ROC : -5.96, RSI : 35.58, STOCH (14,3) : 17.04, STOCH RSI : 0.27, UO : 43.80, Williams %R : -82.96), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Merck & Company Inc. in the last 12-months were: David Michael Williams (Option Excercise at a value of $128 598), Jannie Oosthuizen (Option Excercise at a value of $184 006), Jannie Oosthuizen (Sold 54 622 shares of value $5 445 371 ), Jennifer Zachary (Option Excercise at a value of $4 227 433), Jennifer Zachary (Sold 240 691 shares of value $24 205 655 ), Joseph Romanelli (Sold 5 000 shares of value $541 101 ), Kenneth C. Frazier (Option Excercise at a value of $0), Kenneth C. Frazier (Sold 2 172 853 shares of value $216 848 622 ), Richard R. DeLuca (Option Excercise at a value of $0), Richard R. DeLuca (Sold 164 557 shares of value $16 499 094 ), Rita A. Karachun (Option Excercise at a value of $0), Rita A. Karachun (Sold 31 997 shares of value $3 210 684 ), Robert M. Davis (Option Excercise at a value of $0), Robert M. Davis (Sold 167 613 shares of value $17 169 839 ), Sanat Chattopadhyay (Option Excercise at a value of $12 368 125), Sanat Chattopadhyay (Sold 250 449 shares of value $27 084 010 ), Steven C. Mizell (Option Excercise at a value of $0), Steven C. Mizell (Sold 71 251 shares of value $7 227 494 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.
CEO: Robert M. Davis
Telephone: +1 908 740-4000
Address: 2000 Galloping Hill Road, Kenilworth 07033, NJ, US
Number of employees: 74 000
Wed, 07 Jun 2023 09:55 GMT Merck & Company (MRK) Gets a Buy from SVB Securities- TipRanks. All rights reserved.
Mon, 05 Jun 2023 11:15 GMT Merck & Company (MRK) Gets a Hold from BMO Capital- TipRanks. All rights reserved.
Tue, 30 May 2023 16:30 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN), Merck & Company (MRK) and Lexicon Pharmaceuticals (LXRX)- TipRanks. All rights reserved.
Mon, 01 May 2023 16:31 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Day One Biopharmaceuticals (DAWN)- TipRanks. All rights reserved.
Mon, 01 May 2023 09:30 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Dexcom (DXCM)- TipRanks. All rights reserved.
Fri, 28 Apr 2023 09:25 GMT Merck & Company (MRK) Receives a Hold from Morgan Stanley- TipRanks. All rights reserved.
Tue, 18 Apr 2023 12:39 GMT Merck & Company (MRK) Gets a Buy from Jefferies- TipRanks. All rights reserved.
Mon, 17 Apr 2023 10:35 GMT Merck & Company (MRK) Receives a Hold from Wells Fargo- TipRanks. All rights reserved.
Mon, 17 Apr 2023 10:25 GMT Merck & Company (MRK) Receives a Buy from Citigroup- TipRanks. All rights reserved.
Mon, 17 Apr 2023 03:15 GMT Merck & Company (MRK) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Sun, 16 Apr 2023 10:12 GMT Merck on the Verge of Prometheus Acquisition Report- TipRanks. All rights reserved.
Thu, 13 Apr 2023 08:25 GMT Merck & Company (MRK) was upgraded to a Buy Rating at Citigroup- TipRanks. All rights reserved.
Mon, 10 Apr 2023 08:15 GMT Merck & Company (MRK) Gets a Buy from Mizuho Securities- TipRanks. All rights reserved.
Fri, 17 Mar 2023 09:01 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Quest Diagnostics (DGX) and Fusion Pharmaceuticals (FUSN)- TipRanks. All rights reserved.
Tue, 07 Mar 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Stoke Therapeutics (STOK) and Day One Biopharmaceuticals (DAWN)- TipRanks. All rights reserved.
Tue, 07 Mar 2023 10:45 GMT Merck & Company (MRK) Receives a Buy from Bank of America Securities- TipRanks. All rights reserved.
Tue, 07 Mar 2023 09:50 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Adaptimmune Therapeutics (ADAP)- TipRanks. All rights reserved.
Fri, 03 Feb 2023 11:05 GMT Merck & Company (MRK) Gets a Buy from Bank of America Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.